References
- Murray BE. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis 1991; 163: 1185–1194
- Bauer, AW, Kirby, WMM, Sherris, JC, et al. Antibiotic susceptibility testing by a standardized single disc method. Am J Clin Pathol 1966; 45: 493–496
- Performance standards for antimicrobial disc susceptibility tests. Approved Standard M2-A4, NCCLS. Villanova, Pa. 1990
- Brown EH, Spencer RC, Brown JM. The emergence of bacterial resistance in hospitals — a need for continuous surveillance. J Hosp Infect 1990; 15(Suppl A)35–39
- Barber M, Waterworth PM. Antibacterial activity in vitro of fucidin. Lancet 1962; i: 931–932
- Shanson DC. J Antimicrob Chemothera 1990; 125(Suppl B)15–21
- Faber M, Rosdahl VT. Susceptibility of fusidic acid among Danish Staphylococcus aureus strains and fusidic acid consumption. J Antimicrob Chemothera 1990; 25(Suppl B)7–14
- Aswapokee N, Neu HC. A sulfone, beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot 1978; 31: 1238–1243
- Richardson JF, Marples RR. Changing resistance to antimicrobial drugs and resistance typing in clinically significant strains of Staphylococcus epidermidis. J Med Microbiol 1982; 15: 475–484
- Horan, TV, White, JW, Jarvis, WB, et al. Nosocomial infection surveillance. MMWR 1986; 35: 17SS–29SS
- Jones RN. In-vitro evaluation of aminopenicillin — beta-lactamase inhibitor combinations. Drugs 1988; 35(Suppl 7)17–26
- Grimm H. In-vitro comparison of the beta-lactamase — inhibitory action of clavulanic acid and Sulbactam in ampicillin resistant enterobacteria. Arzneimittelforschung Oct, 1987; 37(10)1116–1119
- Eng RHK, Smith SM, Cherubin CE. Beta-lactamase inhibitors and Acinetobacter spp. J Antimicrob Chemothera Sept, 1990; 26(3)449–450
- Patterns of multi-resistance and their clinical significance. Scand J Infect Dis 1991, Suppl 78: 22–53